An International, Multi-centric, Comparative, Randomized, Parallel group, double-blind, placebo-controlled, phase III clinical trial study to evaluate safety and efficacy of the drug products ReliBeta (Reliance Life Sciences Pvt. Ltd.,India) versus Avonex (Biogen Idec Limited, Great Britain) in the treatment of patients with remitting multiple sclerosis and open after-treatment with Interferon β1а - REAV

Trial Profile

An International, Multi-centric, Comparative, Randomized, Parallel group, double-blind, placebo-controlled, phase III clinical trial study to evaluate safety and efficacy of the drug products ReliBeta (Reliance Life Sciences Pvt. Ltd.,India) versus Avonex (Biogen Idec Limited, Great Britain) in the treatment of patients with remitting multiple sclerosis and open after-treatment with Interferon β1а - REAV

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors RCI Syntez
  • Most Recent Events

    • 02 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top